RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has upgraded BioCryst Pharma (NASDAQ:BCRX) from Sector Perform to Outperform and raised the price target from $9 to $10.
September 18, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharma has been upgraded to Outperform by RBC Capital, with a raised price target of $10.
The upgrade from RBC Capital is a positive signal for BioCryst Pharma. It indicates that the analyst believes the company will outperform the market, which could lead to an increase in the stock price. The raised price target also suggests that the analyst sees potential for the stock price to increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100